GSK partner Hansoh posts late-stage trial win for lung cancer drug in China
Seeking Alpha ·
GSK ( GSK ) announced on Friday a Phase 3 trial win in China for risvutatug rezetecan (Ris-Rez), an antibody-drug conjugate that the British drugmaker licensed from its Chinese partner Hansoh Pharmaceutical Group ( HNSPF ) in 2023. The pivotal Phase 3 trial, ARTEMIS-008, conducted in
DYAX Investor Sentiment
Bullish (Long) 54% · Bearish (Short) 46%
218 participants
Related News
- Dividend Roundup: Costco, Phillips 66, Abbot Labs, AbbVie, and more
- Caldwell names John Blank COO
- Agronomics reports June-end NAV of 12.93p/share
- Apollo set to break its five-year-old dealmaking record in 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- UBS Sees 19% Upside for European Stocks, Lifts Stoxx 600 Target